The bispecific neutralizer therapeutics market is projected to develop at an annualized pace of ~16%

Roots Analysis has done a detailed study on Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 370+ page report, which features 90+ figures and 110+ tables, please visit Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030

Key Market Insights
 With two approved drugs and close to 300 clinical / preclinical product candidates, the bispecific antibody therapeutics pipeline has evolved significantly over the past few years
 The pipeline features drug candidates that target a wide range of biological antigens based on different antibody formats through novel mechanisms of action; more than 50% of these act by retargeting or activation of T-Cells
 To gain a competitive edge in the market, developers are actively exploring novel biological targets and mechanisms of action to treat diverse disease indications
 Although start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also actively engaged
 In order to cater to the evolving needs of developers, technology providers have established presence across different regions; the US and EU have emerged as the key hubs
 Close to 50,000 patients were estimated to have been enrolled in clinical trials evaluating bispecific antibody therapeutics, across various geographical locations and phases of development
 The increasing interest of stakeholders in this domain can also be gauged by the rising product development / commercialization, R&D and technology licensing deals being signed across various regions
 Given the complexities associated with the development of bispecific antibodies, contract organizations have become an indispensable part of the development and manufacturing process of antibody therapeutics

Leave a Reply

Your email address will not be published. Required fields are marked *